Bruton's disease, in other terms X-linked agammaglobulinemia (XLA), is the first reported primary immunodeficiency in 1952, caused by a single genetic defect. The development of B cell is under control of signals transmitted by the B-cell antigen receptor (BCR) complex. Lyn, Syk, and Bruton's tyrosine kinase (BTK) are cytoplasmic protein tyrosine kinases. XLA is caused by mutations in the Btk gene, and Btk mutations are responsible for 85% of all antibody deficiencies. Btk mutation interrupts the B-cell development at the pre-B-cell stage, resulting in the absence of B lymphocytes and plasma cells in peripheral blood and peripheral lymphoid tissues. Up till now, 380 unique mutations have been identified. Autosomal recessive forms of agammaglobulinemia also result in B-cell defects, but more severe bacterial infections are seen in XLA patients due to absolute block in early B-cell development. All serum immunoglobulin isotypes are decreased, and antibody production especially against vaccine antigens is impaired. Most of the XLA patients have clinical signs and symptoms after 6 to 9 months of age due to diminished protective maternal antibodies transmitted through placenta. The most frequent symptoms are recurrent upper and lower respiratory tract infections, some of them may suffer from neutropenia. These patients are susceptible to enteroviral infection, which causes chronic meningoencephalitis and dermatomyositis-like syndrome. Recurrent respiratory tract infections lead to chronic lung disease and bronchiectasis. These infections may disable the patient and result in death. B-cell dysfunction may also cause autoimmunity and B-cell malignancies. Patients with recurrent infections have to be evaluated for the primary immunodeficiency. X-linked agammaglobulinemia has to be considered with low serum IgG, IgA,